Comparative coronary risks of apixaban, rivaroxaban and dabigatran: a meta-analysis and adjusted indirect comparison

AIMS: There are concerns regarding increased risk of acute coronary syndrome with dabigatran. We aimed to assess whether alternative treatment options such as rivaroxaban or apixaban carry a similar risk as compared with dabigatran. METHODS: We searched MEDLINE and EMBASE for randomized controlled t...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Br J Clin Pharmacol
Glavni autori: Loke, Yoon K, Pradhan, Shiva, Yeong, Jessica Ka-yan, Kwok, Chun Shing
Format: Artigo
Jezik:Inglês
Izdano: BlackWell Publishing Ltd 2014
Teme:
Reviews
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4239965/
https://ncbi.nlm.nih.gov/pubmed/24617578
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bcp.12376
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items